SlideShare a Scribd company logo
1 of 43
Download to read offline
DeepVenousThrombosis
Dr.Udai Othman Alghanmi
Meeqat General Hospital
ER Head
DeepVenousThrombosis
• Deep vein thrombosis (DVT) is a condition in
which a blood clot (thrombus) forms in one or
more of the deep veins in your body, usually in
your legs.
Blood Flow
• Superficial to deep veins
• 100-150ml blood fills in calf (Peripheral Heart)
and deep veins
• Calf contracts, valves in perforators close and
blood goes up the deep veins
• Coming up next: Pathophysiology
Pathophysiology
• Is a manifestation of Venous Thromboembolism
• Virchow’s triad:
• Venous Stasis
By anything obstructing or slowing flow of venous blood
• Activation of Coagulation(hypercoagulable state)
Biochemical imbalance between circulating factors
• Vein Damage
Intrinsic or Extrinsic
Development ofThrombosis
• Microscopic thrombus formation and dissolution is
continuous process
• Increased stasis (more microthrombi not washed away
by movement), procoagulant factors, endothelial injury,
favors coagulation more than fibrinolysis, thus a
thrombus
• Coagulation is by Intrinsic or Extrinsic pathway
Virchow’sTriad
Summary of risk factors
• A summary of risk factors is as follows:
• Age 30 year old x 30= 80 year old
• Immobilization longer than 3 days
• Pregnancy and the postpartum period
• Major surgery in previous 4 weeks
• Malignancy (abnormal coagulation, pressure,
chemotherapy)
• Long plane or car trips (> 4 hours) in previous 4
weeks
• Cancer
• Previous DVT
• Anatomical Variations
Summary of risk factors
• Stroke
• Acute myocardial infarction (AMI)
• Congestive heart failure (CHF)
• Sepsis
• Nephrotic syndrome
• Ulcerative colitis
• Multiple trauma
• CNS/spinal cord injury
• Burns
• Lower extremity fractures, injury
• Systemic lupus erythematosus (SLE) and the lupus anticoagulant
• Behçet syndrome
• Homocystinuria
• Polycythemia rubra vera
Summary of risk factors
• Thrombocytosis
• PICC Line> CVC
• Inherited disorders of coagulation/fibrinolysis
• Antithrombin III deficiency
• Protein C deficiency
• Protein S deficiency
• Prothrombin 20210A mutation
• Factor V Leiden
• Dysfibrinogenemias and disorders of plasminogen activation
• Intravenous (IV) drug abuse
• Oral contraceptives
• Estrogens
• Heparin-induced thrombocytopenia (HIT)
SIGNS AND SX
• Pain
• Limb Edema
• Tenderness
• Warmth or Erythema
• Can be present or absent, unilateral or bilateral,
mild or severe
• Presentation can be of Pulmonary Embolism,
sudden coughing, haemoptysis, sharp chest pain,
rapid breathing or shortness of breath, light
headedness.
Deep venous thrombosis dvt
Physical Examination
• Homan’s sign
Calf pain on dorsiflexion of foot
Positive in less than 33% of DVT patients and
more than 50% in patients without DVT
Warning: it must be noted that it is of
little diagnostic value and is theoretically
dangerous because of the possibility of
dislodgement of loose clot
Physical Examination
• Warmth on area of the clot
• Tense leg
• Red or discolored skin
• The most common abnormal hue is reddish
purple from venous engorgement and
obstruction. Can be cyanotic or white.
• Signs and symptoms depending upon the cause.
Deep venous thrombosis dvt
Workup
• Wells Score
Low pretest probabilty
• Go for a D Dimer test
• D-dimer levels remain elevated in DVT for about
7 days
• Negative value rules out in low pretest
probability
• Negative result in high pretest probability, has
no value, start anti coagulation nonetheless and
go for ultrasound.
Intermediate to High Pretest
Probability of DVT
• Ultrasonography is recommended
• Doppler Ultrasound can depict absent or
abnormal flow even if clot isn’t visible in normal
ultrasound.
Venography
• Radiography of a vein after injection of a
radiopaque fluid.
• Conclusive diagnosis historically required
invasive and expensive venography, which is still
considered the criterion standard. Since 1990,
the diagnosis has been obtained noninvasively
by means of sonographic examination.
CBC and Coagulation Profile
• Can look for
• Polycythemia
• Leucocytosis
• Thrombocytosis
• Low PT, APTT, hypercoaguable state
Further Imaging
• CT Scan and MRI if required
• Suspecting iliac vein or inferior vena caval
thrombosis
Who to manage inpatient
• Suspected or proven PE
• Significant CV or pulmonary comorbidity
• Ileofemoral DVT
• Contraindication to anticoagulation
• Disorder of Coagulation
• Pregnancy
• Morbid obesity 150kg+
• Renal Failure
• No compliance, far from hospital, resistance to
therapy, no close follow up.
Leg Elevation
Treatment
• The primary objective for the treatment of DVT
are to prevent a PULMONARY EMBOLUS.
• The mainstay of treatment is
ANTICOAGULATION
• Heparin, Vit K antagonists (Warfarin), and
Factor Xa inhibitors(Fondaparinux)
• Anticoagulation resolves immediate symptoms,
intervention is often to reduce 75%long term risk
of PTS
Who not to anticoagulate
• Intracranial Bleeding
• Severe Active Bleeding
• Recent brain, spinal cord, eye surgery
• Pregnancy
• Malignant hypertension
• Relative contraindications include Recent Major
surgery, recent CVA, severe Thrombocytopenia
Guidelines forAnticoagulation
• Admitted patients are treated with LMWH,
Unfractionated heparin (UFH), Fondaparinux.
• Warfarin 5mg PO is initiated and overlapped for
about 5 days until the INR is >2 for 24 hours.
Unfractionated Heparin
• Standard of care in admitted patients with DVT before
LMWH.
• Prevents extension of thrombus and reduce PE risk
• Heparin must be overlapped for 4-5 days with warfarin
till INR>2
• Because of initial transient hypercoaguable state induced
byWarfarin
IV heparin Protocol
• Initial bolus of 80U/kg
• Constant maintenance of 18u/kg/hr
• Half life 60-90 min
• 1ml contains 5000u
• Check the aPTT or heparin activity level 6 hrs after bolus
and adjust infusion rate accordingly
• Continue to check the aPTT or heparin every 6 hrs, until
2 successful values therapeutic
• Monitor aPTT, hematocrit, Platelets every 24 hrs (HIT)
• aPTT is 21-35 sec usually, therapeutic is 1.5 times 50+
LMW
H
• Clexane (Enoxaparin)
• Increased Bioavailability, prolonged Half Life.
• Treatment of choice in eligible patients.
• 1mg/kg q12 hours leading to therapeutic peak
0.5-1 iu/mL
• Antagonist?
Fondaparinux
• Inhibits factor Xa interrupts blood coagulation
• Generally does not increase PT or PTT
• Dose: <50kg: 5 mg SC once daily
• 50-100 kg: 7.5 Sc once daily
• >100kg 10mg SC once daily
• Patients not responding to Heparin
• Prophylaxis of DVT in patient of HIT until patient
can switch to Warfarin 2.5 mg SC daily
• Antagonist?
Warfarin
• Warfarin interferes with hepatic synthesis of vitamin K–
dependent coagulation factors.
• Initiate warfarin on day 1 or 2 of LMWH or
unfractionated heparin therapy and overlap until desired
INR, THEN discontinue heparin
• Start 10 mg PO for 2 days in healthy individuals, 2-5 mg
PO/IV qDay for 2 days
• Check INR after 2 days and adjust dose according to
results
• Typical maintenance dose ranges between 2 and 10
mg/day
• Maintain an INR of 2.0-3.0
Treatment duration
• Maintain an INR of 2.0-3.0
• Surgery-provoked DVT or PE: Treatment duration of 3 months
• Transient (reversible) risk factor-induced DVT or PE: Treatment
duration of 3 months
• First unprovoked proximal DVT or PE with low or moderate
bleeding risk: Extended treatment consideration with periodic (ie,
annual) risk-benefit analysis
• First unprovoked proximal DVT or PE with high bleeding risk:
Treatment duration of 3 months
Treatment duration
• First unprovoked distal DVT regardless of bleeding risk:
Treatment duration of 3 months
• Second unprovoked DVT or PE with low or moderate
bleeding risk: Extended treatment
• Second unprovoked DVT or PE with high bleeding risk:
Treatment duration of 3 months
• DVT/PE and active cancer: Extended treatment, with
periodic risk-benefit analysis (ACCP recommends
LMWH over vitamin K antagonist therapy)
Treatment follow up
• Regular check up on INR, around a week
• Warning signs prompting immediate contact
with doctor, stopping warfarin.
• Bleeding from any site in body.
• it is generally considered dangerous to have
an INR above 4.0. An INR above 5.0 may
require a medical dose of vitamin K to bring
the INR down to a lower level.
Endovascular Intervention
• Indications for intervention include the relatively rare phlegmasia
or symptomatic inferior vena cava thrombosis that responds poorly
to anticoagulation alone, or symptomatic iliofemoral or
femoropopliteal DVT in patients with a low risk of bleeding.
• The goals of endovascular therapy include reducing the severity and
duration of lower-extremity symptoms, preventing pulmonary
embolism, diminishing the risk of recurrent venous thrombosis, and
preventing postthrombotic syndrome.
Endovascular Intervension Procedures
• Percutaneous transcatheter treatment of
patients with deep venous thrombosis (DVT)
consists of thrombus removal with catheter-
directed thrombolysis, mechanical
thrombectomy, angioplasty, and/or stenting of
venous obstructions.
SurgicalThrombectomy
• Surgical thrombus removal has traditionally
been used in patients with massive swelling and
phlegmasia cerulea dolens
InferiorVenaCava Filters
• Inferior vena cava to trap emboli and minimize venous stasis.
Inferior vena cava filter is a mechanical barrier to the flow of
emboli larger than 4 mm.
• Confirmed acute proximal DVT or acute PE in patient with
contraindication for anticoagulation (this remains the most
common indication for inferior vena cava filter placement)
• Recurrent thromboembolism while on anticoagulation
• Active bleeding complications requiring termination of
anticoagulation therapy
• Early ambulation on day 2 after initiation of
outpatient anticoagulant therapy in addition to
effective compression is strongly recommended.
• The regular use of graduated elastic compression
stockings reduced the incidence of PTS by 50%
DVT Prophylaxis
PostThrombotic Syndrome
• PTS can affect 23-60% of patients in the two years
following DVT of the leg.
• Signs and symptoms of PTS in the leg may include:
• pain (aching or cramping)
• heaviness
• itching or tingling
• swelling (edema)
• varicose veins
• brownish or reddish skin discoloration
• ulcer
Prevention
• prevention of initial and recurrent DVT
• early ambulation
• use of compression stockings
• Electrostimulation devices
• anticoagulant medications.
Deep venous thrombosis dvt
Treatment
• proper leg elevation
• compression therapy with elastic stockings
• wound care for leg ulcers
• angioplasty and vascular stents in proximal thrombosed
veins by an experienced physician can provide
significant relief of swelling and healing of skin ulcers
• Compression bandages are useful to treat edemas

More Related Content

What's hot (20)

Varicose vein
Varicose veinVaricose vein
Varicose vein
 
Dvt diagnosis and management
Dvt   diagnosis and managementDvt   diagnosis and management
Dvt diagnosis and management
 
deep vein thrombosis
deep vein thrombosisdeep vein thrombosis
deep vein thrombosis
 
Splenectomy
SplenectomySplenectomy
Splenectomy
 
dialated cardiomyopathies
dialated cardiomyopathiesdialated cardiomyopathies
dialated cardiomyopathies
 
Varicocele
VaricoceleVaricocele
Varicocele
 
peripherial arterial disease
peripherial arterial diseaseperipherial arterial disease
peripherial arterial disease
 
Deep Vein Thrombosis
Deep Vein ThrombosisDeep Vein Thrombosis
Deep Vein Thrombosis
 
Acute limb ischemia
Acute limb ischemiaAcute limb ischemia
Acute limb ischemia
 
Hydrocele management
Hydrocele managementHydrocele management
Hydrocele management
 
Pulmonary Embolism
Pulmonary EmbolismPulmonary Embolism
Pulmonary Embolism
 
Pulmonary thromboembolism
Pulmonary thromboembolismPulmonary thromboembolism
Pulmonary thromboembolism
 
Surgery hernia
Surgery   herniaSurgery   hernia
Surgery hernia
 
Varicose Vein
Varicose VeinVaricose Vein
Varicose Vein
 
Dvt
DvtDvt
Dvt
 
Peripheral Vascular Diseases
Peripheral Vascular DiseasesPeripheral Vascular Diseases
Peripheral Vascular Diseases
 
Buerger’s disease
Buerger’s diseaseBuerger’s disease
Buerger’s disease
 
Mitral stenosis
Mitral stenosisMitral stenosis
Mitral stenosis
 
Lymphoedema
LymphoedemaLymphoedema
Lymphoedema
 
Inguinal hernia
Inguinal herniaInguinal hernia
Inguinal hernia
 

Similar to Deep venous thrombosis dvt

Deep Vein Thrombosis
Deep Vein ThrombosisDeep Vein Thrombosis
Deep Vein ThrombosisGauhar Azeem
 
Deep vein thrombosis shivaom short
Deep vein thrombosis shivaom shortDeep vein thrombosis shivaom short
Deep vein thrombosis shivaom shortShivaom Chaurasia
 
Case presentation on dvt (1)
Case presentation on dvt (1)Case presentation on dvt (1)
Case presentation on dvt (1)Vishali Vishu
 
4_5801031263770905642.pptx
4_5801031263770905642.pptx4_5801031263770905642.pptx
4_5801031263770905642.pptxAbisiniyaAbe
 
Deep Vein Thrombosis
Deep Vein ThrombosisDeep Vein Thrombosis
Deep Vein Thrombosisibrahimkiwan1
 
Approach to a child with bleeding for UGs
Approach to a child with bleeding for UGsApproach to a child with bleeding for UGs
Approach to a child with bleeding for UGsCSN Vittal
 
DVT AND ANEURYSMS.pptx
DVT AND ANEURYSMS.pptxDVT AND ANEURYSMS.pptx
DVT AND ANEURYSMS.pptxSnehaSaraSam
 
TREATMENT FOR MEDICALLY COMPROMISED PATIENT
TREATMENT FOR MEDICALLY COMPROMISED PATIENTTREATMENT FOR MEDICALLY COMPROMISED PATIENT
TREATMENT FOR MEDICALLY COMPROMISED PATIENTQueenie Delgado
 
Dvt and pulmonary embolism
Dvt and pulmonary embolismDvt and pulmonary embolism
Dvt and pulmonary embolismAnkit Gajjar
 
venous thromboembolism.pptx
venous thromboembolism.pptxvenous thromboembolism.pptx
venous thromboembolism.pptxpalaksamtani2
 
Uppergibleeding 150402032909-conversion-gate01-converted
Uppergibleeding 150402032909-conversion-gate01-convertedUppergibleeding 150402032909-conversion-gate01-converted
Uppergibleeding 150402032909-conversion-gate01-convertedMohammad Rehan
 
Thrombocytopenia
ThrombocytopeniaThrombocytopenia
ThrombocytopeniaDilmo Yeldo
 
Cardiac Transplantation
Cardiac TransplantationCardiac Transplantation
Cardiac TransplantationUsman Shams
 
IMMUNE thrombocytopeni.ppt
IMMUNE thrombocytopeni.pptIMMUNE thrombocytopeni.ppt
IMMUNE thrombocytopeni.pptKKRAKESH1
 

Similar to Deep venous thrombosis dvt (20)

Deep Vein Thrombosis
Deep Vein ThrombosisDeep Vein Thrombosis
Deep Vein Thrombosis
 
Deep vein thrombosis shivaom short
Deep vein thrombosis shivaom shortDeep vein thrombosis shivaom short
Deep vein thrombosis shivaom short
 
Case presentation on dvt (1)
Case presentation on dvt (1)Case presentation on dvt (1)
Case presentation on dvt (1)
 
4_5801031263770905642.pptx
4_5801031263770905642.pptx4_5801031263770905642.pptx
4_5801031263770905642.pptx
 
Anticoaglant
AnticoaglantAnticoaglant
Anticoaglant
 
DVT Management.pdf
DVT Management.pdfDVT Management.pdf
DVT Management.pdf
 
Deep Vein Thrombosis
Deep Vein ThrombosisDeep Vein Thrombosis
Deep Vein Thrombosis
 
Approach to a child with bleeding for UGs
Approach to a child with bleeding for UGsApproach to a child with bleeding for UGs
Approach to a child with bleeding for UGs
 
DVT AND ANEURYSMS.pptx
DVT AND ANEURYSMS.pptxDVT AND ANEURYSMS.pptx
DVT AND ANEURYSMS.pptx
 
TREATMENT FOR MEDICALLY COMPROMISED PATIENT
TREATMENT FOR MEDICALLY COMPROMISED PATIENTTREATMENT FOR MEDICALLY COMPROMISED PATIENT
TREATMENT FOR MEDICALLY COMPROMISED PATIENT
 
Dvt&amp;pe
Dvt&amp;peDvt&amp;pe
Dvt&amp;pe
 
dvt-good.ppt
dvt-good.pptdvt-good.ppt
dvt-good.ppt
 
Anticoagulants
AnticoagulantsAnticoagulants
Anticoagulants
 
Dvt and pulmonary embolism
Dvt and pulmonary embolismDvt and pulmonary embolism
Dvt and pulmonary embolism
 
VTE.pptx
VTE.pptxVTE.pptx
VTE.pptx
 
venous thromboembolism.pptx
venous thromboembolism.pptxvenous thromboembolism.pptx
venous thromboembolism.pptx
 
Uppergibleeding 150402032909-conversion-gate01-converted
Uppergibleeding 150402032909-conversion-gate01-convertedUppergibleeding 150402032909-conversion-gate01-converted
Uppergibleeding 150402032909-conversion-gate01-converted
 
Thrombocytopenia
ThrombocytopeniaThrombocytopenia
Thrombocytopenia
 
Cardiac Transplantation
Cardiac TransplantationCardiac Transplantation
Cardiac Transplantation
 
IMMUNE thrombocytopeni.ppt
IMMUNE thrombocytopeni.pptIMMUNE thrombocytopeni.ppt
IMMUNE thrombocytopeni.ppt
 

More from MEEQAT HOSPITAL

Updated conscious sedation course.ppt
Updated conscious sedation course.pptUpdated conscious sedation course.ppt
Updated conscious sedation course.pptMEEQAT HOSPITAL
 
Updated algorithm of ER – ICU - In - patients guidelines.pptx
Updated algorithm of ER – ICU -  In - patients guidelines.pptxUpdated algorithm of ER – ICU -  In - patients guidelines.pptx
Updated algorithm of ER – ICU - In - patients guidelines.pptxMEEQAT HOSPITAL
 
Blood Bank Lecture .pptx
Blood Bank Lecture .pptxBlood Bank Lecture .pptx
Blood Bank Lecture .pptxMEEQAT HOSPITAL
 
Sepsis and septic shock guidelines 2021. part 1
Sepsis and septic shock guidelines 2021. part 1Sepsis and septic shock guidelines 2021. part 1
Sepsis and septic shock guidelines 2021. part 1MEEQAT HOSPITAL
 
Sepsis hemodynamic update part two
Sepsis hemodynamic update      part twoSepsis hemodynamic update      part two
Sepsis hemodynamic update part twoMEEQAT HOSPITAL
 
sepsis SSC 2021 Updates Ventilation and additional therapy
sepsis SSC 2021 Updates Ventilation and additional therapysepsis SSC 2021 Updates Ventilation and additional therapy
sepsis SSC 2021 Updates Ventilation and additional therapyMEEQAT HOSPITAL
 
Surviving sepsis compaign (adults) Guidelines updates 2021. “Long Term Outcom...
Surviving sepsis compaign (adults)Guidelines updates 2021.“Long Term Outcom...Surviving sepsis compaign (adults)Guidelines updates 2021.“Long Term Outcom...
Surviving sepsis compaign (adults) Guidelines updates 2021. “Long Term Outcom...MEEQAT HOSPITAL
 
Medication error, nursing responsibility
Medication error, nursing responsibilityMedication error, nursing responsibility
Medication error, nursing responsibilityMEEQAT HOSPITAL
 
Continuous renal replacement therapy crrt
Continuous renal replacement therapy crrtContinuous renal replacement therapy crrt
Continuous renal replacement therapy crrtMEEQAT HOSPITAL
 
Chest intubation indications,precautions and management
Chest intubation indications,precautions and managementChest intubation indications,precautions and management
Chest intubation indications,precautions and managementMEEQAT HOSPITAL
 
Covid19 corona management -كوفيد19
Covid19 corona management -كوفيد19Covid19 corona management -كوفيد19
Covid19 corona management -كوفيد19MEEQAT HOSPITAL
 
Conscious sedation course
Conscious sedation courseConscious sedation course
Conscious sedation courseMEEQAT HOSPITAL
 
Medical permission for patient
Medical permission for patientMedical permission for patient
Medical permission for patientMEEQAT HOSPITAL
 

More from MEEQAT HOSPITAL (20)

Updated conscious sedation course.ppt
Updated conscious sedation course.pptUpdated conscious sedation course.ppt
Updated conscious sedation course.ppt
 
fatal asthma.pptx
fatal asthma.pptxfatal asthma.pptx
fatal asthma.pptx
 
Updated algorithm of ER – ICU - In - patients guidelines.pptx
Updated algorithm of ER – ICU -  In - patients guidelines.pptxUpdated algorithm of ER – ICU -  In - patients guidelines.pptx
Updated algorithm of ER – ICU - In - patients guidelines.pptx
 
Blood Bank Lecture .pptx
Blood Bank Lecture .pptxBlood Bank Lecture .pptx
Blood Bank Lecture .pptx
 
Post covid -19 syndrome
Post covid -19 syndromePost covid -19 syndrome
Post covid -19 syndrome
 
Sepsis and septic shock guidelines 2021. part 1
Sepsis and septic shock guidelines 2021. part 1Sepsis and septic shock guidelines 2021. part 1
Sepsis and septic shock guidelines 2021. part 1
 
Sepsis hemodynamic update part two
Sepsis hemodynamic update      part twoSepsis hemodynamic update      part two
Sepsis hemodynamic update part two
 
sepsis SSC 2021 Updates Ventilation and additional therapy
sepsis SSC 2021 Updates Ventilation and additional therapysepsis SSC 2021 Updates Ventilation and additional therapy
sepsis SSC 2021 Updates Ventilation and additional therapy
 
Sepsis scoring
Sepsis  scoringSepsis  scoring
Sepsis scoring
 
Surviving sepsis compaign (adults) Guidelines updates 2021. “Long Term Outcom...
Surviving sepsis compaign (adults)Guidelines updates 2021.“Long Term Outcom...Surviving sepsis compaign (adults)Guidelines updates 2021.“Long Term Outcom...
Surviving sepsis compaign (adults) Guidelines updates 2021. “Long Term Outcom...
 
Medication error, nursing responsibility
Medication error, nursing responsibilityMedication error, nursing responsibility
Medication error, nursing responsibility
 
Continuous renal replacement therapy crrt
Continuous renal replacement therapy crrtContinuous renal replacement therapy crrt
Continuous renal replacement therapy crrt
 
Bed sore management
Bed sore managementBed sore management
Bed sore management
 
Chest intubation indications,precautions and management
Chest intubation indications,precautions and managementChest intubation indications,precautions and management
Chest intubation indications,precautions and management
 
Portable ventilator
Portable ventilatorPortable ventilator
Portable ventilator
 
Covid19 corona management -كوفيد19
Covid19 corona management -كوفيد19Covid19 corona management -كوفيد19
Covid19 corona management -كوفيد19
 
Sedation
SedationSedation
Sedation
 
Conscious sedation course
Conscious sedation courseConscious sedation course
Conscious sedation course
 
Electronic medica file
Electronic medica fileElectronic medica file
Electronic medica file
 
Medical permission for patient
Medical permission for patientMedical permission for patient
Medical permission for patient
 

Recently uploaded

AUDIENCE THEORY -- FANDOM -- JENKINS.pptx
AUDIENCE THEORY -- FANDOM -- JENKINS.pptxAUDIENCE THEORY -- FANDOM -- JENKINS.pptx
AUDIENCE THEORY -- FANDOM -- JENKINS.pptxiammrhaywood
 
How to Add a New Field in Existing Kanban View in Odoo 17
How to Add a New Field in Existing Kanban View in Odoo 17How to Add a New Field in Existing Kanban View in Odoo 17
How to Add a New Field in Existing Kanban View in Odoo 17Celine George
 
HED Office Sohayok Exam Question Solution 2023.pdf
HED Office Sohayok Exam Question Solution 2023.pdfHED Office Sohayok Exam Question Solution 2023.pdf
HED Office Sohayok Exam Question Solution 2023.pdfMohonDas
 
Benefits & Challenges of Inclusive Education
Benefits & Challenges of Inclusive EducationBenefits & Challenges of Inclusive Education
Benefits & Challenges of Inclusive EducationMJDuyan
 
Diploma in Nursing Admission Test Question Solution 2023.pdf
Diploma in Nursing Admission Test Question Solution 2023.pdfDiploma in Nursing Admission Test Question Solution 2023.pdf
Diploma in Nursing Admission Test Question Solution 2023.pdfMohonDas
 
How to Use api.constrains ( ) in Odoo 17
How to Use api.constrains ( ) in Odoo 17How to Use api.constrains ( ) in Odoo 17
How to Use api.constrains ( ) in Odoo 17Celine George
 
How to Make a Field read-only in Odoo 17
How to Make a Field read-only in Odoo 17How to Make a Field read-only in Odoo 17
How to Make a Field read-only in Odoo 17Celine George
 
The Stolen Bacillus by Herbert George Wells
The Stolen Bacillus by Herbert George WellsThe Stolen Bacillus by Herbert George Wells
The Stolen Bacillus by Herbert George WellsEugene Lysak
 
2024.03.23 What do successful readers do - Sandy Millin for PARK.pptx
2024.03.23 What do successful readers do - Sandy Millin for PARK.pptx2024.03.23 What do successful readers do - Sandy Millin for PARK.pptx
2024.03.23 What do successful readers do - Sandy Millin for PARK.pptxSandy Millin
 
Human-AI Co-Creation of Worked Examples for Programming Classes
Human-AI Co-Creation of Worked Examples for Programming ClassesHuman-AI Co-Creation of Worked Examples for Programming Classes
Human-AI Co-Creation of Worked Examples for Programming ClassesMohammad Hassany
 
DUST OF SNOW_BY ROBERT FROST_EDITED BY_ TANMOY MISHRA
DUST OF SNOW_BY ROBERT FROST_EDITED BY_ TANMOY MISHRADUST OF SNOW_BY ROBERT FROST_EDITED BY_ TANMOY MISHRA
DUST OF SNOW_BY ROBERT FROST_EDITED BY_ TANMOY MISHRATanmoy Mishra
 
The basics of sentences session 10pptx.pptx
The basics of sentences session 10pptx.pptxThe basics of sentences session 10pptx.pptx
The basics of sentences session 10pptx.pptxheathfieldcps1
 
The Singapore Teaching Practice document
The Singapore Teaching Practice documentThe Singapore Teaching Practice document
The Singapore Teaching Practice documentXsasf Sfdfasd
 
Practical Research 1 Lesson 9 Scope and delimitation.pptx
Practical Research 1 Lesson 9 Scope and delimitation.pptxPractical Research 1 Lesson 9 Scope and delimitation.pptx
Practical Research 1 Lesson 9 Scope and delimitation.pptxKatherine Villaluna
 
Clinical Pharmacy Introduction to Clinical Pharmacy, Concept of clinical pptx
Clinical Pharmacy  Introduction to Clinical Pharmacy, Concept of clinical pptxClinical Pharmacy  Introduction to Clinical Pharmacy, Concept of clinical pptx
Clinical Pharmacy Introduction to Clinical Pharmacy, Concept of clinical pptxraviapr7
 
General views of Histopathology and step
General views of Histopathology and stepGeneral views of Histopathology and step
General views of Histopathology and stepobaje godwin sunday
 
Ultra structure and life cycle of Plasmodium.pptx
Ultra structure and life cycle of Plasmodium.pptxUltra structure and life cycle of Plasmodium.pptx
Ultra structure and life cycle of Plasmodium.pptxDr. Asif Anas
 
CHUYÊN ĐỀ DẠY THÊM TIẾNG ANH LỚP 11 - GLOBAL SUCCESS - NĂM HỌC 2023-2024 - HK...
CHUYÊN ĐỀ DẠY THÊM TIẾNG ANH LỚP 11 - GLOBAL SUCCESS - NĂM HỌC 2023-2024 - HK...CHUYÊN ĐỀ DẠY THÊM TIẾNG ANH LỚP 11 - GLOBAL SUCCESS - NĂM HỌC 2023-2024 - HK...
CHUYÊN ĐỀ DẠY THÊM TIẾNG ANH LỚP 11 - GLOBAL SUCCESS - NĂM HỌC 2023-2024 - HK...Nguyen Thanh Tu Collection
 

Recently uploaded (20)

AUDIENCE THEORY -- FANDOM -- JENKINS.pptx
AUDIENCE THEORY -- FANDOM -- JENKINS.pptxAUDIENCE THEORY -- FANDOM -- JENKINS.pptx
AUDIENCE THEORY -- FANDOM -- JENKINS.pptx
 
How to Add a New Field in Existing Kanban View in Odoo 17
How to Add a New Field in Existing Kanban View in Odoo 17How to Add a New Field in Existing Kanban View in Odoo 17
How to Add a New Field in Existing Kanban View in Odoo 17
 
HED Office Sohayok Exam Question Solution 2023.pdf
HED Office Sohayok Exam Question Solution 2023.pdfHED Office Sohayok Exam Question Solution 2023.pdf
HED Office Sohayok Exam Question Solution 2023.pdf
 
Benefits & Challenges of Inclusive Education
Benefits & Challenges of Inclusive EducationBenefits & Challenges of Inclusive Education
Benefits & Challenges of Inclusive Education
 
Diploma in Nursing Admission Test Question Solution 2023.pdf
Diploma in Nursing Admission Test Question Solution 2023.pdfDiploma in Nursing Admission Test Question Solution 2023.pdf
Diploma in Nursing Admission Test Question Solution 2023.pdf
 
How to Use api.constrains ( ) in Odoo 17
How to Use api.constrains ( ) in Odoo 17How to Use api.constrains ( ) in Odoo 17
How to Use api.constrains ( ) in Odoo 17
 
How to Make a Field read-only in Odoo 17
How to Make a Field read-only in Odoo 17How to Make a Field read-only in Odoo 17
How to Make a Field read-only in Odoo 17
 
Prelims of Kant get Marx 2.0: a general politics quiz
Prelims of Kant get Marx 2.0: a general politics quizPrelims of Kant get Marx 2.0: a general politics quiz
Prelims of Kant get Marx 2.0: a general politics quiz
 
The Stolen Bacillus by Herbert George Wells
The Stolen Bacillus by Herbert George WellsThe Stolen Bacillus by Herbert George Wells
The Stolen Bacillus by Herbert George Wells
 
2024.03.23 What do successful readers do - Sandy Millin for PARK.pptx
2024.03.23 What do successful readers do - Sandy Millin for PARK.pptx2024.03.23 What do successful readers do - Sandy Millin for PARK.pptx
2024.03.23 What do successful readers do - Sandy Millin for PARK.pptx
 
Human-AI Co-Creation of Worked Examples for Programming Classes
Human-AI Co-Creation of Worked Examples for Programming ClassesHuman-AI Co-Creation of Worked Examples for Programming Classes
Human-AI Co-Creation of Worked Examples for Programming Classes
 
DUST OF SNOW_BY ROBERT FROST_EDITED BY_ TANMOY MISHRA
DUST OF SNOW_BY ROBERT FROST_EDITED BY_ TANMOY MISHRADUST OF SNOW_BY ROBERT FROST_EDITED BY_ TANMOY MISHRA
DUST OF SNOW_BY ROBERT FROST_EDITED BY_ TANMOY MISHRA
 
The basics of sentences session 10pptx.pptx
The basics of sentences session 10pptx.pptxThe basics of sentences session 10pptx.pptx
The basics of sentences session 10pptx.pptx
 
Finals of Kant get Marx 2.0 : a general politics quiz
Finals of Kant get Marx 2.0 : a general politics quizFinals of Kant get Marx 2.0 : a general politics quiz
Finals of Kant get Marx 2.0 : a general politics quiz
 
The Singapore Teaching Practice document
The Singapore Teaching Practice documentThe Singapore Teaching Practice document
The Singapore Teaching Practice document
 
Practical Research 1 Lesson 9 Scope and delimitation.pptx
Practical Research 1 Lesson 9 Scope and delimitation.pptxPractical Research 1 Lesson 9 Scope and delimitation.pptx
Practical Research 1 Lesson 9 Scope and delimitation.pptx
 
Clinical Pharmacy Introduction to Clinical Pharmacy, Concept of clinical pptx
Clinical Pharmacy  Introduction to Clinical Pharmacy, Concept of clinical pptxClinical Pharmacy  Introduction to Clinical Pharmacy, Concept of clinical pptx
Clinical Pharmacy Introduction to Clinical Pharmacy, Concept of clinical pptx
 
General views of Histopathology and step
General views of Histopathology and stepGeneral views of Histopathology and step
General views of Histopathology and step
 
Ultra structure and life cycle of Plasmodium.pptx
Ultra structure and life cycle of Plasmodium.pptxUltra structure and life cycle of Plasmodium.pptx
Ultra structure and life cycle of Plasmodium.pptx
 
CHUYÊN ĐỀ DẠY THÊM TIẾNG ANH LỚP 11 - GLOBAL SUCCESS - NĂM HỌC 2023-2024 - HK...
CHUYÊN ĐỀ DẠY THÊM TIẾNG ANH LỚP 11 - GLOBAL SUCCESS - NĂM HỌC 2023-2024 - HK...CHUYÊN ĐỀ DẠY THÊM TIẾNG ANH LỚP 11 - GLOBAL SUCCESS - NĂM HỌC 2023-2024 - HK...
CHUYÊN ĐỀ DẠY THÊM TIẾNG ANH LỚP 11 - GLOBAL SUCCESS - NĂM HỌC 2023-2024 - HK...
 

Deep venous thrombosis dvt

  • 2. DeepVenousThrombosis • Deep vein thrombosis (DVT) is a condition in which a blood clot (thrombus) forms in one or more of the deep veins in your body, usually in your legs.
  • 3. Blood Flow • Superficial to deep veins • 100-150ml blood fills in calf (Peripheral Heart) and deep veins • Calf contracts, valves in perforators close and blood goes up the deep veins • Coming up next: Pathophysiology
  • 4. Pathophysiology • Is a manifestation of Venous Thromboembolism • Virchow’s triad: • Venous Stasis By anything obstructing or slowing flow of venous blood • Activation of Coagulation(hypercoagulable state) Biochemical imbalance between circulating factors • Vein Damage Intrinsic or Extrinsic
  • 5. Development ofThrombosis • Microscopic thrombus formation and dissolution is continuous process • Increased stasis (more microthrombi not washed away by movement), procoagulant factors, endothelial injury, favors coagulation more than fibrinolysis, thus a thrombus • Coagulation is by Intrinsic or Extrinsic pathway
  • 7. Summary of risk factors • A summary of risk factors is as follows: • Age 30 year old x 30= 80 year old • Immobilization longer than 3 days • Pregnancy and the postpartum period • Major surgery in previous 4 weeks • Malignancy (abnormal coagulation, pressure, chemotherapy) • Long plane or car trips (> 4 hours) in previous 4 weeks • Cancer • Previous DVT • Anatomical Variations
  • 8. Summary of risk factors • Stroke • Acute myocardial infarction (AMI) • Congestive heart failure (CHF) • Sepsis • Nephrotic syndrome • Ulcerative colitis • Multiple trauma • CNS/spinal cord injury • Burns • Lower extremity fractures, injury • Systemic lupus erythematosus (SLE) and the lupus anticoagulant • Behçet syndrome • Homocystinuria • Polycythemia rubra vera
  • 9. Summary of risk factors • Thrombocytosis • PICC Line> CVC • Inherited disorders of coagulation/fibrinolysis • Antithrombin III deficiency • Protein C deficiency • Protein S deficiency • Prothrombin 20210A mutation • Factor V Leiden • Dysfibrinogenemias and disorders of plasminogen activation • Intravenous (IV) drug abuse • Oral contraceptives • Estrogens • Heparin-induced thrombocytopenia (HIT)
  • 10. SIGNS AND SX • Pain • Limb Edema • Tenderness • Warmth or Erythema • Can be present or absent, unilateral or bilateral, mild or severe • Presentation can be of Pulmonary Embolism, sudden coughing, haemoptysis, sharp chest pain, rapid breathing or shortness of breath, light headedness.
  • 12. Physical Examination • Homan’s sign Calf pain on dorsiflexion of foot Positive in less than 33% of DVT patients and more than 50% in patients without DVT Warning: it must be noted that it is of little diagnostic value and is theoretically dangerous because of the possibility of dislodgement of loose clot
  • 13. Physical Examination • Warmth on area of the clot • Tense leg • Red or discolored skin • The most common abnormal hue is reddish purple from venous engorgement and obstruction. Can be cyanotic or white. • Signs and symptoms depending upon the cause.
  • 16. Low pretest probabilty • Go for a D Dimer test • D-dimer levels remain elevated in DVT for about 7 days • Negative value rules out in low pretest probability • Negative result in high pretest probability, has no value, start anti coagulation nonetheless and go for ultrasound.
  • 17. Intermediate to High Pretest Probability of DVT • Ultrasonography is recommended • Doppler Ultrasound can depict absent or abnormal flow even if clot isn’t visible in normal ultrasound.
  • 18. Venography • Radiography of a vein after injection of a radiopaque fluid. • Conclusive diagnosis historically required invasive and expensive venography, which is still considered the criterion standard. Since 1990, the diagnosis has been obtained noninvasively by means of sonographic examination.
  • 19. CBC and Coagulation Profile • Can look for • Polycythemia • Leucocytosis • Thrombocytosis • Low PT, APTT, hypercoaguable state
  • 20. Further Imaging • CT Scan and MRI if required • Suspecting iliac vein or inferior vena caval thrombosis
  • 21. Who to manage inpatient • Suspected or proven PE • Significant CV or pulmonary comorbidity • Ileofemoral DVT • Contraindication to anticoagulation • Disorder of Coagulation • Pregnancy • Morbid obesity 150kg+ • Renal Failure • No compliance, far from hospital, resistance to therapy, no close follow up.
  • 23. Treatment • The primary objective for the treatment of DVT are to prevent a PULMONARY EMBOLUS. • The mainstay of treatment is ANTICOAGULATION • Heparin, Vit K antagonists (Warfarin), and Factor Xa inhibitors(Fondaparinux) • Anticoagulation resolves immediate symptoms, intervention is often to reduce 75%long term risk of PTS
  • 24. Who not to anticoagulate • Intracranial Bleeding • Severe Active Bleeding • Recent brain, spinal cord, eye surgery • Pregnancy • Malignant hypertension • Relative contraindications include Recent Major surgery, recent CVA, severe Thrombocytopenia
  • 25. Guidelines forAnticoagulation • Admitted patients are treated with LMWH, Unfractionated heparin (UFH), Fondaparinux. • Warfarin 5mg PO is initiated and overlapped for about 5 days until the INR is >2 for 24 hours.
  • 26. Unfractionated Heparin • Standard of care in admitted patients with DVT before LMWH. • Prevents extension of thrombus and reduce PE risk • Heparin must be overlapped for 4-5 days with warfarin till INR>2 • Because of initial transient hypercoaguable state induced byWarfarin
  • 27. IV heparin Protocol • Initial bolus of 80U/kg • Constant maintenance of 18u/kg/hr • Half life 60-90 min • 1ml contains 5000u • Check the aPTT or heparin activity level 6 hrs after bolus and adjust infusion rate accordingly • Continue to check the aPTT or heparin every 6 hrs, until 2 successful values therapeutic • Monitor aPTT, hematocrit, Platelets every 24 hrs (HIT) • aPTT is 21-35 sec usually, therapeutic is 1.5 times 50+
  • 28. LMW H • Clexane (Enoxaparin) • Increased Bioavailability, prolonged Half Life. • Treatment of choice in eligible patients. • 1mg/kg q12 hours leading to therapeutic peak 0.5-1 iu/mL • Antagonist?
  • 29. Fondaparinux • Inhibits factor Xa interrupts blood coagulation • Generally does not increase PT or PTT • Dose: <50kg: 5 mg SC once daily • 50-100 kg: 7.5 Sc once daily • >100kg 10mg SC once daily • Patients not responding to Heparin • Prophylaxis of DVT in patient of HIT until patient can switch to Warfarin 2.5 mg SC daily • Antagonist?
  • 30. Warfarin • Warfarin interferes with hepatic synthesis of vitamin K– dependent coagulation factors. • Initiate warfarin on day 1 or 2 of LMWH or unfractionated heparin therapy and overlap until desired INR, THEN discontinue heparin • Start 10 mg PO for 2 days in healthy individuals, 2-5 mg PO/IV qDay for 2 days • Check INR after 2 days and adjust dose according to results • Typical maintenance dose ranges between 2 and 10 mg/day • Maintain an INR of 2.0-3.0
  • 31. Treatment duration • Maintain an INR of 2.0-3.0 • Surgery-provoked DVT or PE: Treatment duration of 3 months • Transient (reversible) risk factor-induced DVT or PE: Treatment duration of 3 months • First unprovoked proximal DVT or PE with low or moderate bleeding risk: Extended treatment consideration with periodic (ie, annual) risk-benefit analysis • First unprovoked proximal DVT or PE with high bleeding risk: Treatment duration of 3 months
  • 32. Treatment duration • First unprovoked distal DVT regardless of bleeding risk: Treatment duration of 3 months • Second unprovoked DVT or PE with low or moderate bleeding risk: Extended treatment • Second unprovoked DVT or PE with high bleeding risk: Treatment duration of 3 months • DVT/PE and active cancer: Extended treatment, with periodic risk-benefit analysis (ACCP recommends LMWH over vitamin K antagonist therapy)
  • 33. Treatment follow up • Regular check up on INR, around a week • Warning signs prompting immediate contact with doctor, stopping warfarin. • Bleeding from any site in body. • it is generally considered dangerous to have an INR above 4.0. An INR above 5.0 may require a medical dose of vitamin K to bring the INR down to a lower level.
  • 34. Endovascular Intervention • Indications for intervention include the relatively rare phlegmasia or symptomatic inferior vena cava thrombosis that responds poorly to anticoagulation alone, or symptomatic iliofemoral or femoropopliteal DVT in patients with a low risk of bleeding. • The goals of endovascular therapy include reducing the severity and duration of lower-extremity symptoms, preventing pulmonary embolism, diminishing the risk of recurrent venous thrombosis, and preventing postthrombotic syndrome.
  • 35. Endovascular Intervension Procedures • Percutaneous transcatheter treatment of patients with deep venous thrombosis (DVT) consists of thrombus removal with catheter- directed thrombolysis, mechanical thrombectomy, angioplasty, and/or stenting of venous obstructions.
  • 36. SurgicalThrombectomy • Surgical thrombus removal has traditionally been used in patients with massive swelling and phlegmasia cerulea dolens
  • 37. InferiorVenaCava Filters • Inferior vena cava to trap emboli and minimize venous stasis. Inferior vena cava filter is a mechanical barrier to the flow of emboli larger than 4 mm. • Confirmed acute proximal DVT or acute PE in patient with contraindication for anticoagulation (this remains the most common indication for inferior vena cava filter placement) • Recurrent thromboembolism while on anticoagulation • Active bleeding complications requiring termination of anticoagulation therapy
  • 38. • Early ambulation on day 2 after initiation of outpatient anticoagulant therapy in addition to effective compression is strongly recommended. • The regular use of graduated elastic compression stockings reduced the incidence of PTS by 50%
  • 40. PostThrombotic Syndrome • PTS can affect 23-60% of patients in the two years following DVT of the leg. • Signs and symptoms of PTS in the leg may include: • pain (aching or cramping) • heaviness • itching or tingling • swelling (edema) • varicose veins • brownish or reddish skin discoloration • ulcer
  • 41. Prevention • prevention of initial and recurrent DVT • early ambulation • use of compression stockings • Electrostimulation devices • anticoagulant medications.
  • 43. Treatment • proper leg elevation • compression therapy with elastic stockings • wound care for leg ulcers • angioplasty and vascular stents in proximal thrombosed veins by an experienced physician can provide significant relief of swelling and healing of skin ulcers • Compression bandages are useful to treat edemas